reported better-than-expected third-quarter earnings.
The biotechnology company said it earned $2.9 million, or 5 cents a diluted share, compared with a loss of $2.1 million, or 4 cents a share, in the year-ago period. Five analysts expected the company to earn 4 cents a share for the quarter, according to
First Call/Thomson Financial
Total revenue rose 3% to $80.7 million from $78.7 million last year.